1978 Sicaf Sif S.A.Gg 1978 ... Net Worth

The estimated Net Worth of 1978 Sicaf Sif S.A.Gg 1978 ... is at least $628 millió dollars as of 14 September 2022. 1978 1978 owns over 345,014 units of Royalty Pharma plc stock worth over $613,414,514 and over the last 2 years 1978 sold RPRX stock worth over $14,621,693.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

1978 1978 RPRX stock SEC Form 4 insiders trading

1978 has made over 1 trades of the Royalty Pharma plc stock since 2022, according to the Form 4 filled with the SEC. Most recently 1978 sold 345,014 units of RPRX stock worth $14,621,693 on 14 September 2022.

The largest trade 1978's ever made was selling 345,014 units of Royalty Pharma plc stock on 14 September 2022 worth over $14,621,693. On average, 1978 trades about 345,014 units every 0 days since 2022. As of 14 September 2022 1978 still owns at least 22,081,156 units of Royalty Pharma plc stock.

You can see the complete history of 1978 1978 stock trades at the bottom of the page.

What's 1978 1978's mailing address?

1978's mailing address filed with the SEC is 18 AVENUE DE LA PORTE NEUVE18 AVENUE DE LA PORTE NEUVE, , LUXEMBOURGLUXEMBOURG, N4N4, L-2227L-2227.

Insiders trading at Royalty Pharma plc

Over the last 4 years, insiders at Royalty Pharma plc have traded over $863,995,127 worth of Royalty Pharma plc stock and bought 5,330,350 units worth $152,553,456 . The most active insiders traders include David C Hodgson, William E Ford és Capital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of $7,420,205. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth $13,221,100.

What does Royalty Pharma plc do?

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi

Complete history of 1978 1978 stock trades at Royalty Pharma plc

Royalty Pharma plc executives and stock owners

Royalty Pharma plc executives and other stock owners filed with the SEC include:

• Pablo Gerardo Legorreta,
  Founder, Chairman & CEO
• Christopher Hite,
  Vice Chairman & Exec. VP
• George Wingate Lloyd,
  Exec. VP of Investments & Gen. Counsel
• Dr. James Folmar Reddoch Ph.D.,
  Exec. VP, Chief Scientific Officer and Co-Head of Research & Investments
• Terrance P. Coyne,
  Exec. VP & CFO
• Alessandra Sassun,
  Head of Human Capital
• Carolyn Judith Rubin J.D.,
  Director of Compliance
• George Grofik C.F.A., CPA,
  Sr. VP and Head of Investor Relations & Communications
• Kristin Stafford,
  Sr. VP & Chief Accounting Officer
• Sandy Balkin Ph.D.,
  Sr. VP of Strategy & Analytics
• Dr. Marshall Urist M.D., Ph.D.,
  Exec. VP and Co-Head of Research & Investments
• Mario Germano Mgg Strategic...,
  
• Capital Partners Gp, L.L.C....,
  
• Marshall Urist,
  EVP, Research & Investments
• Management Ltd Giuliani Mar...,
  
• Mario Germano Skyeline Mana...,
  
• William E Ford,
  Director
• George W. Lloyd,
  EVP, Investments & CLO
• Pablo G. Legorreta,
  CEO, Chairman of the Board
• Gregory Norden,
  Director
• Errol B Desouza,
  Director
• Bonnie L Bassler,
  Director
• Catherine M. Engelbert,
  Director
• Ted W Love,
  Director
• Christopher Hite,
  EVP & Vice Chairman
• Rory B Riggs,
  Director
• Terrance P. Coyne,
  EVP & CFO
• Henry A Fernandez,
  Director
• Mario Germano Giuliani,
  
• James F. Reddoch,
  EVP & Chief Scientific Officer
• Mario Germano Mgg Strategic...,
  
• Mario Germano Skyeline Mana...,
  
• 1978 Sicaf Sif S.A. Gg St...,
  
• Mario Germano Mgg Strategic...,
  
• 1978 Sicaf Sif S.A.Gg 1978 ...,
  
• David C Hodgson,
  Director